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SUMMARY:
Rare diseases are characterised by their low prevalence
(less than 1/2,000) and their heterogeneity. They affect both
children and adults anywhere in the world. From the medical
perspective, rare diseases are characterised by the large number
and broad diversity of disorders and symptoms that vary not
only from disease to disease, but also within the same disease.
Main characteristics of rare diseases include:
· Rare diseases are often chronic, progressive,
degenerative, and often life-threatening
· Rare diseases are disabling: the quality of life of patients
is often compromised by the lack or loss of autonomy
· High level of pain and suffering for the patient and his/
her family
· No existing effective cure
· There are between 6000 and 8000 rare diseases
· 75% of rare diseases affect children
· 30% of rare disease patients die before the age of 5
· 80% of rare diseases have identified genetic origins.
Other rare diseases are the result of infections (bacterial or viral),
allergies and environmental causes, or are degenerative and
proliferative.
Beyond the diversity of the diseases, rare disease patients
and their families are confronted with the same wide range of
difficulties arising directly from the rarity of these pathologies.
The period between the emergence of the first symptoms and
the appropriate diagnosis involves unacceptable and highly
risky delays, as well as wrong diagnosis leading to inaccurate
treatments. Living with a rare disease has implications in all areas
of life, whether school, choice of future work, leisure time with
friends, or affective life. It may lead to stigmatisation, isolation,
exclusion from social community, discrimination for insurance
subscription (health insurance, travel insurance, mortgage), and
often reduced professional opportunities.
Innovative treatments are often unevenly available in the
EU because of delays in price determination and/or
reimbursement decision, lack of experience of the treating
physicians (not enough physicians involved in rare diseases
clinical trials), and the absence of treatment consensus
recommendations.
It is fundamental to realise that rare diseases can affect
any family at any time. It is not just “something terrible that
happens to other people”. It is a very cruel reality that can
happen to anyone, either when having a child or in the course
of one’s own life.
In fact, the terminology “rare diseases” only highlights
the characteristic of rarity of the complex and heterogeneous
mosaic of an estimated 7,000 life-threatening and heavily
debilitating conditions.
The rare diseases for which a simple and effective
preventive treatment is available are being screened for, as part
of public health policy. But this is not enough, and it is essential
for public authorities to consider rare diseases as a Public Health
priority and take action to concretely support patients and
families affected by rare diseases.
As underlined in the Background Paper on Orphan
Diseases for the World Health Organisation Report on Priority
Medicines for Europe and the World, “despite the growing
public awareness of rare diseases in the last one or two decades,
there are still many gaps in knowledge related to the
development of treatment for rare diseases. Policymakers have
to realise that rare diseases are a crucial health issue for about
30 million people in the EU”.
A good medication for rare disease patients is a
medication that is both available in the country where they live
and affordable. If one of these two factors is missing, the drug
is of little use.
Personalized medicine however is an emerging term for a
medical philosophy that uses a person’s individual clinical,
genetic, genomic, and environmental information to tailor a
treatment plan that will maximize efficacy and safety for that
individual. While the technology offers much promise, it also is
also challenged by some ethical and social questions in both
its clinical application and in its research enterprise. Questions
about privacy, safety, phenotypical expression, drug interactions,
and genetic vs. social group identities will challenge clinical
pharmacogenetics.
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A rare disease is a disease that occurs infrequently or
rarely in the general population. In order to be considered as
rare, each specific disease cannot affect more than a limited
number of people out of the whole population, defined in
Europe as less than 1 in 2,000 citizens. Rare diseases are
characterised by a broad diversity of disorders and symptoms
that vary not only from disease to disease but also from patient  / JofIMAB 2011, vol. 17, book 1 /  117
to patient suffering from the same disease. Relatively common
symptoms can hide underlying rare diseases, leading to
misdiagnosis.
From the medical perspective, rare diseases are
characterised by the large number and broad diversity of
disorders and symptoms that vary not only from disease to
disease, but also within the same disease. The same condition
can have very different clinical manifestations from one person
affected to the other. For many disorders, there is a broad
diversity of subtypes of the same disease. It is estimated that
between 5.000 and 7.000 distinct rare diseases exist today,
affecting patients in their physical capabilities, their mental
abilities, in their behaviour and sensorial capacities. Many
disabilities can coexist for a given person, and this is defined as
a polyhandicap.
Rare diseases also differ widely in terms of severity, but
in average the life expectancy of rare disease patients is
significantly reduced. The impact on life expectancy varies
greatly from one disease to the other; some cause death at birth,
many are degenerative or life threatening, whilst others are
compatible with a normal life if diagnosed in time and properly
managed and/or treated.
80% of rare diseases have identified genetic origins,
involving one or several genes or chromosomal abnormalities.
They can be inherited or derived from de novo gene mutation
or from a chromosomal abnormality. They concern between 3%
and 4% of births. Other rare diseases are caused by infections
(bacterial or viral), or allergies, or are due to degenerative,
proliferative or teratogenic (chemicals, radiations, etc) causes.
Some rare diseases are also caused by a combination of genetic
and environmental factors.
There is also great diversity in the age at which the first
symptoms occur. Symptoms of many rare diseases appear at birth
or in childhood, including Infantile Spinal Muscular Atrophy,
Neurofibromatosis, Osteogenesis Imperfecta, ect. In some cases,
the first symptoms of the disease, such as Neurofibromatosis,
may occur in childhood, but this does not prevent much heavier
symptoms to occur at a later stage of life. Other rare diseases,
such as Huntington disease, Spinocerebellar Ataxias and thyroid
cancer are specific to adulthood.
Despite this great diversity, rare diseases have some
major common traits. The main characteristics including:
· Lack of access to correct diagnosis
· Delay in diagnosis
· Lack of quality information on the disease
· Lack of scientific knowledge of the disease
· Heavy social consequences for patients
· Lack of appropriate quality healthcare
· Inequities and difficulties in access to treatment and
care
Because rare disease patients are a minority, there is a
lack of public awareness. These diseases do not represent a
public health priority, and little research is performed. The market
is so narrow for each disease that the pharmaceutical industry
is reticent to invest in research and to develop treatments for
rare diseases.
Patients with such conditions deserve the same quality,
safety and efficacy in medicinal products as other patients. The
European union, had adopted Regulation1 141/2000 on orphan
medical products. The purpose of this Regulation is to lay down
a Community procedure for the designation of medicinal
products as orphan medicinal products and to provide incentives
for the research, development and placing on the market of
designated orphan medicinal products.
Orphan drugs are medicinal products intended for the
diagnosis, prevention or treatment of rare diseases. These drugs
are called “orphan” because, under normal market conditions, it
is not cost-effective for the pharmaceutical industry to develop
and market products intended for only a small number of patients
suffering from rare conditions. The drugs developed for this
unprofitable market would not be financially viable for the patent-
holding manufacturer. For drug companies, the cost of bringing
an orphan medicinal product to the market would not be
recovered by the expected sales of the product. For this reason,
governments and rare disease patient organisations have
emphasised the need for economic incentives to encourage drug
companies to develop and market medicines intended for the
“orphaned” rare disease patients.
A medicinal product shall be designated as an orphan
medicinal product if its sponsor can establish:
a) that it is intended for the diagnosis, prevention or
treatment of a life-threatening or chronically debilitating
condition affecting not more than five in 10 thousand persons
in the Community when the application is made, or that it is
intended for the diagnosis, prevention or treatment of a life-
threatening, seriously debilitating or serious and chronic
condition in the Community and that without incentives it is
unlikely that the marketing of the medicinal product in the
Community would generate sufficient return to justify the
necessary investment; and
b) that there exists no satisfactory method of diagnosis,
prevention or treatment of the condition in question that has
been authorised in the Community or, if such method exists, that
the medicinal product will be of significant benefit to those
affected by that condition.
Experience in the United States of America and Japan
shows that the strongest incentive for industry to invest in the
development and marketing of orphan medicinal products is
where there is a prospect of obtaining market exclusivity for a
certain number of years during which part of the investment
might be recovered.
Advances in deciphering the human genome have
brought hope to millions of people suffering from genetic
1 Regulation (EC) No 141/2000 of the European Parliament
and of the Council of 16 December 1999 on orphan medicinal
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diseases, many of which are rare and disabling. However with
this renewed hope comes the risk of using genetic information
to discriminate against those who have a genetic condition, risk
or predisposition.
The US has taken an important decision to explicitly ban
this type of discrimination with the recently enacted Genetic
Information Anti Discrimination Act (GINA). GINA forbids
insurance companies to ask for genetic tests to be performed or
to access existing results in order to set premiums or determine
eligibility of enrolment. Employers are also prohibited from using
genetic information in hiring, firing or promoting employees. The
legislation, initiated by the National Organisation for Rare
Disorders (NORD), which was under discussion for 13 years,
was finally enacted thanks to the relentless advocacy efforts of
patient groups such as Genetic Alliance, who managed to
convince a large number of senators to back the bill.
GINA not only protects the privacy of each individual
but it also encourages them to seek tests which could help
diagnose their condition or extend their life expectancy without
fear of misuse or discrimination. It will also have a positive effect
on research since fear of discrimination will no longer dissuade
large numbers of people from participating in clinical trial,
speeding up the research and development process for targeted
drugs and treatments. This is especially worrying when applied
in the workplace and by insurance companies.
In Europe similar but uneven steps are being taken in
this direction. The Committee of Ministers of the Council of
Europe has adopted an Additional Protocol to the Convention
on Human Rights and Biomedicine concerning Genetic Testing
for Health Purposes. The purpose of the document is to set legal
rules to protect fundamental human rights with regards to the
latest advances in genetic testing.
The Protocol addresses the protection of private life and
access to information collected though genetic testing.
Although, the Protocol does not specifically address genetic
testing for employment and insurance purposes, it speaks
undoubtedly against any kind of discrimination based on genetic
testing by linking all justification of genetic testing to health
purposes. In this way, only a direct medical benefit could be cited
as justification for the performance of a predictive genetic test.
Although the European Council’s Convention and its
Protocols are important because they represent an official
standard at the European level and serves as a guidelines for
Member States, its major weakness is that it is non-binding and
not all countries adhere to it. Some countries have not ratified
the Convention because they fear it might restrict research
possibilities. Moreover, they have not passed specific anti-
discrimination legislation.
For example, there are currently no laws banning
insurance companies from accessing genetic tests in the UK.
However, insurers and the government have agreed on a
voluntary five-year ban, which has been extended until 2014.
Similar moratoria are in place in Germany and the Netherlands.
Under the UK voluntary ban, nobody has to disclose genetic
test results to insurers unless they are buying a policy which
will pay out more than £500,000 on life insurance or £300,000 on
critical illness insurance, and provided that the test is approved
by the Genetics and Insurance Committee. One such test is the
one for Huntington Disease, a rare neurological monogenetic
disease, which has a high predictability rate.
At the other end of the spectrum are countries like France
where insurance companies cannot ask for a test or use
information provided by such a test and it is a criminal offence
to attempt to obtain or supply test results for any other purpose
than medical or scientific purposes. Similar legislation exists in
Spain where insurance companies are not allowed to carry out
genetic tests on their customers, nor make genetic diagnosis a
condition for issuing a policy.
Overall, the rules regarding genetic testing in Europe vary
from country to country, and safeguards against discrimination
by the insurance industry are less explicit than in the US. The
explanation might lie in the differences in health protection
systems. Whilst in the US the cost of insurance is carried mostly
by employers (mutuality based) in most European countries the
burden of insurance is spread out throughout society (solidarity
based).
Families and health care workers frequently complain
about the extreme difficulty in taking the necessary administrative
steps required to receive social benefits. Major and arbitrary
disparities exist between countries - and even between regions
within the same country - in the allocation of financial aid,
income support and reimbursement of medical costs. Usually in
Europe, treatment costs incurred are often higher than they are
for other diseases because of the rarity of the disease and the
limited number of specialised centres. In most cases, a significant
proportion of these expenses is born exclusively by the families,
thereby generating an additional inequality between rich rare
disease patients and poor rare disease patients. Travel costs to
specialised centres are high in terms of time off work and
financial cost.
In a family where a child has a rare disease, most often
one of the parents either completely stops or significantly
reduces work remunerated outside home. As a consequence,
while expenses increase dramatically, incomes is considerably
reduced. In the case of an adult rare disease patient who is well
enough to be able to work, the work hours must be adapted to
allow for medical visits and appropriate care. In terms of logistics,
much remains to be done to ensure real equality between a
disabled and a healthy citizen.
For some rare diseases, such as fragile X syndrome and
cystic fibrosis, treatment protocols and defined medical, social
and educational programmes exist in certain countries, as well
as more or less well-targeted screening programmes.
The European Commission has launched a public
consultation in view of modernising rules on the transparency
of Member States’ decisions regarding the pricing and
reimbursement of medicines. The consultation invites all
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Directive 89/105/EEC2.  The objective of the consultation, which
continues from 28.03.2011 to 25.05.2011 is to seek the views of
interested parties to determine how the existing EU rules on the
transparency of pricing and reimbursement procedures for
medicines may be modernised. At present, the Transparency
Directive applies exclusively to medicinal products. The
consultation also aims to assess its relevance to the medical
devices sector.
Within this context of raising awareness of rare diseases
in Europe, the European Commission launched Eurobarometer
survey – published on 28 February 2011. According to this
survey, åuropeans have a relatively accurate understanding of
what rare diseases areð but detailed knowledge and awareness
remain low. 63% of Europeans correctly define rare diseases as
diseases affecting a limited number of people and requiring very
specific care. However, some misconceptions exist with 14%
who believe that these are conditions which nobody can do
anything about or that nobody cares about.
Almost one in six European citizens is personally affected
(17%) or through knowing somebody who is suffering from a
rare disease (13%). However, 40% of Europeans have never heard
of anyone who suffers from a rare disease.
Almost all agree that national health authorities should
provide specific support to people suffering from rare diseases
(96%) and fully reimburse their medication even if it is very
expensive (93%). There is widespread support for policy
initiatives aiming at increasing cooperation at European level,
granting full access to care for patients in other Member States
and introducing national strategies for rare diseases.
An overwhelming majority of respondents in every
Member State – in many cases 90% or more – supports resource
allocation to various actions which tackle rare diseases in various
areas, such as strengthening research cooperation, easing access
to drugs and laboratory tests and giving support to families and
patient organisations.
An overwhelming majority of Europeans support the idea
that national health authorities should give specific support to
people suffering from rare diseases and that they should fully
reimburse the cost of medication developed to treat such
patients. However, the European public is divided on whether
rare diseases should be made a priority at national level when
considering other major health issues which exist.
Almost all (96%) agree that people suffering from a rare
disease need specific support from national health authorities.
More than nine in ten Europeans (93%) agree with the statement
that the cost of developing drugs to treat people suffering from
rare diseases should be fully reimbursed by the national health
care system even if they are expensive. Nearly two-thirds (64%)
totally agree with the statement.
An overwhelming majority (95%) of Europeans agree that
there should be more European cooperation in order to help the
limited number of people suffering from rare diseases more
efficiently. The same proportion believe that people suffering
from a rare disease should have the right to access appropriate
care in another EU Member State. In addition, nine in ten citizens
(90%) agree that every EU Member State should have a National
Plan or Strategy on rare diseases.
The European Commission and the national health
authorities of the EU Member States have adopted several
initiatives to help people suffering from rare diseases. When
asked whether such support is justified, the European public
express their strong agreement. Over 90% of respondents
consider that it is justified to allocate resources to each of the
actions in the areas of research, access to treatment,
communication and patient support.
The majority of respondents in every Member State with
the exception of Portugal find it totally justified to allocate
resources to provide additional support for families with a
member suffering a rare disease. Respondents in Cyprus, Spain
Greece, Malta, Slovenia and Bulgaria are particularly supportive
in this respect. A small minority in each country find allocating
resources to support families unjustified, the highest level of
opposition (7%) being seen in Austria and in Sweden.
Among the European public there is a widespread
willingness to improve the treatment of rare diseases. However
this willingness is instinctive and empathetic rather than based
on actual knowledge. Future policy needs to be accompanied
by education and awareness-building to increase the general
recognition and visibility of rare diseases which in terms of real
knowledge is very low amongst the general public.
Address for correspondence:
Mariela Yaneva - Deliverska
mob: +359 88 757 49 73
e-mail: yanevamariela@yahoo.com
1. European Commission, Euro-
barometer, European awareness of Rare
Diseases, Feb. 2011
2. EURORDIS, The Voice of 12,000
Patients: Experiences & Expectations of
Rare Disease Patients on Diagnosis & Care
in Europe, 2009.
3. EURORDIS, Rare diseases:
understanding this Public Health Priority,
2005.
4.  Council for Responsible Genetics,
Position Paper on Genetic Discrimination,
2001.
BIBLIOGRAPHY:
2  Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal
products for human use and their inclusion in the scope of national health insurance systems (OJ L 40, 11.2.1989, p. 8–11)